Trial Information
Diagnostic Contribution of XENETIX® CT PERFUSION in Pre-therapeutical Assessment of Hepatocellular Carcinoma
Inclusion Criteria:
- Subjects diagnosed for HCC and planned for surgery (lobectomy or transplantation)
within a timeframe of 30 days between first imaging procedure used for the study and
surgery.
Exclusion Criteria:
- Subjects who have undergone prior TACE (TransArterial Chemo Embolization), prior RFA
(Radio Frequency Ablation) or prior SIRT (Selected Internal Radio Therapy) within one
year before inclusion.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
Perfusion parameters and histology grade
Outcome Description:
Correlation between perfusion parameters and histology grade using CT perfusion exam and pathology findings
Outcome Time Frame:
within a week before surgery
Safety Issue:
No
Principal Investigator
Hatem Alkadhi
Investigator Role:
Principal Investigator
Investigator Affiliation:
Zurich University Hospital
Authority:
Switzerland: Swissmedic
Study ID:
ISO-44-013
NCT ID:
NCT01639703
Start Date:
April 2012
Completion Date:
June 2014
Related Keywords:
- Hepatocellular Carcinoma
- CT perfusion
- Hepatocellular Carcinoma
- Xenetix
- Contrast agent
- Carcinoma
- Carcinoma, Hepatocellular